american heart association glp 1 Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society Practical Considerations for the Use

This is a huge source of complaints about WeightWatchers

Heres who might benefit most: People with insulin resistance or metabolic syndrome who have chronically elevated insulin levels that increase the production of artery-damaging cholesterol particles People with fatty liver disease and dyslipidemia (abnormal amount of fats in the blood) who need to lower inflammation and stress on the liver, bringing down high triglycerides and inhibiting production of artery-damaging cholesterol particles People whose blood work shows elevated levels of these biomarkers : ApoB : The total count of all plaque forming particles in the blood

PMID: 1704369

SGLT2 Inhibitors No pharmacokinetic interaction studies have identified clinically meaningful changes when empagliflozin, dapagliflozin, or canagliflozin are combined with GLP-1 RAs

The decision to continue, taper, or stop should be individualized, not driven by arbitrary timelines